Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Licenses Gene Therapy Component From Voyager
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Siemens Healthineers Seeks €200M Novartis Deal to Boost Cancer Imaging Business: FT
Earnings Summary: Novartis Beats Q2 Earnings Estimates; Raises 2024 Profit Forecast on Demand for New Drugs
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Core Operating Income Outlook
Vanguard FTSE All-World Ex-US ETF To Go Ex-Dividend On June 21st, 2024 With 0.4589 USD Dividend Per Share
June 19th (Eastern Time) - $Vanguard FTSE All-World ex-US ETF(VEU.US)$ is trading ex-dividend on June 21st, 2024.Shareholders of record on June 21st, 2024 will receive 0.4589 USD dividend per share on
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Novartis, Roche Facing Italy Antitrust Probe Over Lucentis Biosimilar
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
TG Therapeutics Wins VA Contract for Briumvi
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Looking At Novartis's Recent Unusual Options Activity
Vertex Pharma Upgraded at Evercore on Alpine Immune Deal
Intra-Cellular Files Lawsuits Challenging Caplyta Generics
Novartis Pharmaceuticals Canada Announced Health Canada Grants Approval Of The Eye-tracking Neurological Assessment For Multiple Sclerosis For Use In Tracking Disease Progression In People Living With MS
AstraZeneca-Fusion Deal Reignites Radiopharma Space